PIK3CA and breast cancer: In the original studies we have included, most of the patients in the study are postmenopausal patients with BC, so the comparison of the study is mostly combination therapy of PI3K inhibitor+fulvestrant vs. fulvestrant group alone, and the majority of the patients are HR-positive and HER2-negative.